Apeiron Investment Group withdrew its nomination at Sensei Biotherapeutics

Market Cap: $49 million| Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer.

 Background

On November 2, 2022, Apeiron Investment Group Ltd. (11.2%) delivered an open letter to the Board calling them to take immediate action to regain the trust of shareholders and consolidate shareholder support given the steep and continuous decline in shareholder value and the failure of the company’s sole clinical program. Apeiron also highlighted its significant concerns regarding the chronic underperformance, strategic direction and lack of alignment with shareholders. Apeiron concluded the letter by stating that it continues to believe in the company’s potential and is open to, and hopeful of, finding a constructive resolution to address these concerns. To that end, Apeiron stated that it looks forward to continuing to engage with the Board on these issues for the benefit of all stakeholders

On November 21, 2022, Apeiron Investment Group Ltd. (14.5%) issued a press release and open letter  to the Board calling them to take immediate action to regain the trust of the shareholders and consolidate shareholder support given the company’s ongoing decline in shareholder value. The Letter also discusses the best paths forward for the Board, including immediately liquidate the company and return capital to shareholders. The Letter concludes with Apeiron encouraging all other shareholders to express their views and let their voices be heard by reaching out directly to the Board.

On March 9, 2023, Apeiron Investment Group Ltd (11.2%) delivered a letter to the company nominating a slate of three candidates for election to the board at the 2023 AGM. Source

Update

On May 23, 2023, Apeiron Investment Group Ltd entered into a Purchase Agreement with the company pursuant to which the company agreed to purchase 4,454,248 Shares  from Apeiron Investment Group for a purchase price of $1.58 per share. Under the Purchase Agreement, Apeiron also has agreed to withdraw its notice of intent to nominate director candidates for election to the board at the 2023 AGM. Source